Corporate News – Dermata Therapeutics
Market Performance Snapshot
Dermata Therapeutics (ticker DRMA) closed 1.16 % higher on Wednesday, 21 Oct 2026, at 04:48 PM Central Europe time. The stock is currently trading at USD 0.83 on major exchanges. With an outstanding supply of 4 million shares, the company’s market capitalization stands at USD 3.5 million. In the preceding 24 hours, trading volume amounted to roughly USD 157.5 k.
Over the past month, DRMA has declined ‑24.35 %, underscoring the volatility typical of early‑stage biotechs. The simple moving average over the last 200 days is USD 1.37. In its 52‑week cycle, the highest price reached USD 4.66 on 01 26 2026, while the low hit USD 0.60 on 10 14 2026.
Regulatory Update
In a recent filing with the Securities and Exchange Commission (SEC), Dermata Therapeutics announced that it has met the necessary regulatory requirements to proceed with a public offering. The form, submitted via the SEC’s electronic filing system, confirms the effective date for new disclosures that will be available by the end of October. It includes standard corporate information—company name, incorporation state, and contact details—but does not reveal any new business or financial developments. The filing signals to investors and regulators alike that Dermata is now positioned to advance its planned public transaction, with all requisite disclosures slated for public release.
Comparative Context: Peer Activity
The following table summarizes how related stocks performed in the last 24 hours:
| Ticker | 24‑hour Change | Current Price (USD) | Market Capitalization (USD mn) |
|---|---|---|---|
| AUMN (Golden Minerals) | 0 % | 0.21 | 4.0 |
| FFAI (Faraday Future Intelligent E) | –1.33 % | 0.62 | 4.0 |
| QCLS (Q/c) | 0 % | 0.53 | 4.1 |
| HYFM (Hydrofarm) | –5.87 % | 0.77 | 3.9 |
| YCBD (Cbdmd) | +11.21 % | 0.39 | 3.9 |
Dermata’s performance is consistent with the broader trend of volatility among small‑cap biotechnology firms, many of which are navigating regulatory milestones and market uncertainties.
Company Overview
Dermata Therapeutics, Inc. is a clinical‑stage biotechnology enterprise focused on developing therapies for medical and aesthetic skin conditions. The company operates globally and maintains a presence on the Nasdaq exchange. For additional information about its pipeline, clinical programs, and corporate governance, visit the firm’s website at www.dermatarx.com .
